Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Carcinoma, Medullary × Sorafenib × Clear all

Phase

Status

Sponsor Class

OTHER 1 NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Osteosarcoma 2 Stomach Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Lung Neoplasms 1 Hepatoblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Esophageal Neoplasms 1 Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Medullary 1 Carcinoma, Hepatocellular 1 Adenocarcinoma Of Esophagus 1

Interventions

vandetanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 nintedanib 1 mercaptoundecahydrododecaborate 1 Standard of Care 1 Sorafenib 1 Practice Guidelines as Topic 1 Docetaxel 1 4-boronophenylalanine-fructose 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01736878 2013-05-17

SUMMIT

Eanm Research Ltd

Phase 2 Withdrawn

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡